Taro Pharmaceutical Industries Ltd
NYSE:TARO
Intrinsic Value
Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. [ Read More ]
The intrinsic value of one TARO stock under the Base Case scenario is 28.2 USD. Compared to the current market price of 42.26 USD, Taro Pharmaceutical Industries Ltd is Overvalued by 33%.
Valuation Backtest
Taro Pharmaceutical Industries Ltd
Run backtest to discover the historical profit from buying and selling TARO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Taro Pharmaceutical Industries Ltd
Current Assets | 1.3B |
Cash & Short-Term Investments | 902.2m |
Receivables | 230.4m |
Other Current Assets | 214.8m |
Non-Current Assets | 815.8m |
Long-Term Investments | 403.5m |
PP&E | 218.4m |
Intangibles | 17.2m |
Other Non-Current Assets | 176.6m |
Current Liabilities | 374.1m |
Accounts Payable | 51.2m |
Other Current Liabilities | 322.9m |
Non-Current Liabilities | 10m |
Other Non-Current Liabilities | 10m |
Earnings Waterfall
Taro Pharmaceutical Industries Ltd
Revenue
|
610.8m
USD
|
Cost of Revenue
|
-317.5m
USD
|
Gross Profit
|
293.3m
USD
|
Operating Expenses
|
-271.3m
USD
|
Operating Income
|
22m
USD
|
Other Expenses
|
23.6m
USD
|
Net Income
|
45.6m
USD
|
Free Cash Flow Analysis
Taro Pharmaceutical Industries Ltd
What is Free Cash Flow?
TARO Profitability Score
Profitability Due Diligence
Taro Pharmaceutical Industries Ltd's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
Score
Taro Pharmaceutical Industries Ltd's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
TARO Solvency Score
Solvency Due Diligence
Taro Pharmaceutical Industries Ltd's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Score
Taro Pharmaceutical Industries Ltd's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TARO Price Targets Summary
Taro Pharmaceutical Industries Ltd
According to Wall Street analysts, the average 1-year price target for TARO is 43.86 USD with a low forecast of 43.43 USD and a high forecast of 45.15 USD.
Ownership
TARO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
TARO Price
Taro Pharmaceutical Industries Ltd
Average Annual Return | -26.9% |
Standard Deviation of Annual Returns | 11.82% |
Max Drawdown | -79% |
Market Capitalization | 1.6B USD |
Shares Outstanding | 37 580 000 |
Percentage of Shares Shorted | 0.73% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. The firm operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The firm markets over 200 pharmaceutical products in over 25 countries. The firm's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The firm's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one TARO stock under the Base Case scenario is 28.2 USD.
Compared to the current market price of 42.26 USD, Taro Pharmaceutical Industries Ltd is Overvalued by 33%.